COMPANY
Modulation Therapeutics, Inc.
Timeline
Upcoming milestones
- Mar 31, 2027 (ESTIMATED) · Phase 1 · Targeted Alpha Particle Radiotherapy for Metastatic Uveal Melanoma · NCT05496686
Funding
- Government grant — SBIR: $217,685 (annual award, as published), announced Aug 22, 2025. Agency: NIH/NCI. Source: government award database. source ↗
Clinical trials (lead sponsor) 1
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT05496686 | Targeted Alpha Particle Radiotherapy for Metastatic Uveal Melanoma | Phase 1 | Active, not recruiting | Jul 21, 2022 | Mar 31, 2027 (estimated) |
NIH awards 23
- NIH award 5R44CA272064-03 FY2024: $670,441 awarded for that fiscal year; activity R44 (SBIR); PI HAYES, KAREN E; recipient as written: MODULATION THERAPEUTICS, INC., MORGANTOWN, WV. Modulation of cancer induced immun source ↗
- NIH award 4R44CA272064-02 FY2023: $1,301,808 awarded for that fiscal year; activity R44 (SBIR); PI HAYES, KAREN E; recipient as written: MODULATION THERAPEUTICS, INC., MORGANTOWN, WV. Modulation of cancer induced imm source ↗
- NIH award 1R41DK131705-01A1 FY2023: $344,919 awarded for that fiscal year; activity R41 (STTR); PI HAZLEHURST, LORI A; recipient as written: MODULATION THERAPEUTICS, INC., MORGANTOWN, WV. MTI-301 a SCD1 inhibitor for source ↗
- NIH award 1R44CA272064-01A1 FY2022: $399,986 awarded for that fiscal year; activity R44 (SBIR); PI HAYES, KAREN E; recipient as written: MODULATION THERAPEUTICS, INC., MORGANTOWN, WV. Modulation of cancer induced imm source ↗
- NIH award 3R44CA221554-03S1 FY2020: $212,660 awarded for that fiscal year; activity R44 (SBIR); PI HAZLEHURST, LORI A; recipient as written: MODULATION THERAPEUTICS, INC., MORGANTOWN, WV. Mechanism underpinning syner source ↗
- NIH award 5R44CA221554-03 FY2019: $763,695 awarded for that fiscal year; activity R44 (SBIR); PI HAYES, KAREN E; recipient as written: MODULATION THERAPEUTICS, INC., MORGANTOWN, WV. Development of PEGylated MTI-101 f source ↗
- NIH award 5R42CA195946-03 FY2019: $1,236,819 awarded for that fiscal year; activity R42 (STTR); PI COPLAND, JOHN A.; recipient as written: MODULATION THERAPEUTICS, INC., MORGANTOWN, WV. Novel SCD1 inhibitors for trea source ↗
- NIH award 3R44CA221554-02S1 FY2019: $4,318 awarded for that fiscal year; activity R44 (SBIR); PI WATERHOUSE, RIKKI NOEL; recipient as written: MODULATION THERAPEUTICS, INC., MORGANTOWN, WV. Development of PEGylated M source ↗
- NIH award 1R41NS110070-01 FY2019: $258,700 awarded for that fiscal year; activity R41 (STTR); PI HAZLEHURST, LORI A; recipient as written: MODULATION THERAPEUTICS, INC., MORGANTOWN, WV. Development of mitoNEET agonis source ↗
- NIH award 1R43CA235992-01 FY2018: $248,155 awarded for that fiscal year; activity R43 (SBIR); PI GARCIA, JOSE GABRIEL; recipient as written: MODULATION THERAPEUTICS, INC., MORGANTOWN, WV. Development of an a MC1R sel source ↗
- NIH award 4R44CA221554-02 FY2018: $1,161,570 awarded for that fiscal year; activity R44 (SBIR); PI WATERHOUSE, RIKKI NOEL; recipient as written: MODULATION THERAPEUTICS, INC., MORGANTOWN, WV. Development of PEGylated source ↗
- NIH award 2R42CA195946-02A1 FY2018: $763,181 awarded for that fiscal year; activity R42 (STTR); PI COPLAND, JOHN A.; recipient as written: MODULATION THERAPEUTICS, INC., MORGANTOWN, WV. Novel SCD1 inhibitors for trea source ↗
- NIH award 3R44CA221554-01S1 FY2018: $49,975 awarded for that fiscal year; activity R44 (SBIR); PI HAZLEHURST, LORI A; recipient as written: MODULATION THERAPEUTICS, INC., MORGANTOWN, WV. Development of PEGylated MTI- source ↗
- NIH award 1R44CA221554-01 FY2017: $242,056 awarded for that fiscal year; activity R44 (SBIR); PI WATERHOUSE, RIKKI NOEL; recipient as written: MODULATION THERAPEUTICS, INC., MORGANTOWN, WV. Development of PEGylated M source ↗
- NIH award 1R41CA210669-01A1 FY2017: $283,986 awarded for that fiscal year; activity R41 (STTR); PI COPLAND, JOHN A.; recipient as written: MODULATION THERAPEUTICS, INC., MORGANTOWN, WV. Osteopontin-targeted therapy f source ↗
- NIH contract (government contract; not a grant and not an investment round) 261201700035C-0-0-1 FY2017: $1,999,987 awarded for that fiscal year; activity N44 (OTHER_NIH); PI WATERHOUSE, RIKKI; recipient as written: MODULATION THERAPEUTICS, INC., MORGANTOWN, WV source ↗
- NIH award 1R41CA195946-01A1 FY2016: $279,000 awarded for that fiscal year; activity R41 (STTR); PI HAZLEHURST, LORI A; recipient as written: MODULATION THERAPEUTICS, INC., MORGANTOWN, WV. Novel SCD1 inhibitors for tr source ↗
- NIH award 1R41CA196026-01 FY2015: $244,801 awarded for that fiscal year; activity R41 (STTR); PI MCLAUGHLIN, MARK L; recipient as written: MODULATION THERAPEUTICS, INC., MORGANTOWN, WV. Targeting CD137L to MC1R-Expre source ↗
- NIH contract (government contract; not a grant and not an investment round) 261201500067C-0-0-1 FY2015: $299,336 awarded for that fiscal year; activity N43 (OTHER_NIH); PI MCLAUGHLIN, MARK; recipient as written: MODULATION THERAPEUTICS, INC., MORGANTOWN, WV. T source ↗
- NIH award 1R41CA183266-01 FY2014: $225,000 awarded for that fiscal year; activity R41 (STTR); PI MCLAUGHLIN, MARK L; recipient as written: MODULATION THERAPEUTICS, INC., MORGANTOWN, WV. Second generation MTI-101 anal source ↗
- NIH award 1R43CA180308-01 FY2013: $288,301 awarded for that fiscal year; activity R43 (SBIR); PI HAZLEHURST, LORI A; recipient as written: MODULATION THERAPEUTICS, INC., MORGANTOWN, WV. Increasing the efficacy of MTI source ↗
- NIH award 1R43CA171367-01A1 FY2012: $218,817 awarded for that fiscal year; activity R43 (SBIR); PI NAIR, RAJESH R; recipient as written: MODULATION THERAPEUTICS, INC., MORGANTOWN, WV. Targeting CD44 in the bone marro source ↗
- NIH award 1R43CA167998-01A1 FY2012: $156,202 awarded for that fiscal year; activity R43 (SBIR); PI JAIN, PRIYESH; recipient as written: MODULATION THERAPEUTICS, INC., MORGANTOWN, WV. Chemical Optimization Designed to source ↗